NKGen Biotech Ownership 2024 | Who Owns NKGen Biotech Now?


OverviewFinancialsChart

Institutional Ownership

31.65%

Insider Ownership

41.42%

Retail Ownership

26.92%

Institutional Holders

13.00

NKGen Biotech Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----100,557-100.00%-Dec 31, 2023
KARPUS MANAGEMENT, INC.----280,525-100.00%-Dec 31, 2023
BALYASNY ASSET MANAGEMENT L.P.----310,359-100.00%-Dec 31, 2023
RIVERNORTH CAPITAL MANAGEMENT, LLC----580,432-100.00%-Dec 31, 2023
ALBERTA INVESTMENT MANAGEMENT CORP----200,000-100.00%-Dec 31, 2023
WESTCHESTER CAPITAL MANAGEMENT, LLC----105,266-100.00%-Dec 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.----200,000-100.00%-Dec 31, 2023
PERISCOPE CAPITAL INC.----347,994-100.00%-Dec 31, 2023
CLEAR STREET LLC----73,364-100.00%-Dec 31, 2023
DIAMETRIC CAPITAL, LP----471,000-100.00%-Dec 31, 2023
SANDIA INVESTMENT MANAGEMENT LP----471,000-100.00%-Dec 31, 2023
METEORA CAPITAL, LLC----2,122,715-100.00%-Dec 31, 2023
SPARTAN FUND MANAGEMENT INC.----62,987-100.00%-Dec 31, 2023

NKGen Biotech's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----100,557-100.00%-Dec 31, 2023
KARPUS MANAGEMENT, INC.----280,525-100.00%-Dec 31, 2023
BALYASNY ASSET MANAGEMENT L.P.----310,359-100.00%-Dec 31, 2023
RIVERNORTH CAPITAL MANAGEMENT, LLC----580,432-100.00%-Dec 31, 2023
ALBERTA INVESTMENT MANAGEMENT CORP----200,000-100.00%-Dec 31, 2023
WESTCHESTER CAPITAL MANAGEMENT, LLC----105,266-100.00%-Dec 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.----200,000-100.00%-Dec 31, 2023
PERISCOPE CAPITAL INC.----347,994-100.00%-Dec 31, 2023
CLEAR STREET LLC----73,364-100.00%-Dec 31, 2023
DIAMETRIC CAPITAL, LP----471,000-100.00%-Dec 31, 2023
SANDIA INVESTMENT MANAGEMENT LP----471,000-100.00%-Dec 31, 2023
METEORA CAPITAL, LLC----2,122,715-100.00%-Dec 31, 2023
SPARTAN FUND MANAGEMENT INC.----62,987-100.00%-Dec 31, 2023

The largest NKGen Biotech shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of NKGen Biotech (GFOR), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SPARTAN FUND MANAGEMENT INC.----62,987-100.00%-Dec 31, 2023
CLEAR STREET LLC----73,364-100.00%-Dec 31, 2023
JPMORGAN CHASE & CO----100,557-100.00%-Dec 31, 2023
WESTCHESTER CAPITAL MANAGEMENT, LLC----105,266-100.00%-Dec 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.----200,000-100.00%-Dec 31, 2023
ALBERTA INVESTMENT MANAGEMENT CORP----200,000-100.00%-Dec 31, 2023
KARPUS MANAGEMENT, INC.----280,525-100.00%-Dec 31, 2023
BALYASNY ASSET MANAGEMENT L.P.----310,359-100.00%-Dec 31, 2023
PERISCOPE CAPITAL INC.----347,994-100.00%-Dec 31, 2023
SANDIA INVESTMENT MANAGEMENT LP----471,000-100.00%-Dec 31, 2023
DIAMETRIC CAPITAL, LP----471,000-100.00%-Dec 31, 2023
RIVERNORTH CAPITAL MANAGEMENT, LLC----580,432-100.00%-Dec 31, 2023
METEORA CAPITAL, LLC----2,122,715-100.00%-Dec 31, 2023

As of Dec 31 2023, NKGen Biotech's largest institutional buyer is SPARTAN FUND MANAGEMENT INC.. The company purchased -62.99K stocks of GFOR, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
METEORA CAPITAL, LLC----2,122,715-100.00%-Dec 31, 2023
RIVERNORTH CAPITAL MANAGEMENT, LLC----580,432-100.00%-Dec 31, 2023
DIAMETRIC CAPITAL, LP----471,000-100.00%-Dec 31, 2023
SANDIA INVESTMENT MANAGEMENT LP----471,000-100.00%-Dec 31, 2023
PERISCOPE CAPITAL INC.----347,994-100.00%-Dec 31, 2023
BALYASNY ASSET MANAGEMENT L.P.----310,359-100.00%-Dec 31, 2023
KARPUS MANAGEMENT, INC.----280,525-100.00%-Dec 31, 2023
ALBERTA INVESTMENT MANAGEMENT CORP----200,000-100.00%-Dec 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.----200,000-100.00%-Dec 31, 2023
WESTCHESTER CAPITAL MANAGEMENT, LLC----105,266-100.00%-Dec 31, 2023
JPMORGAN CHASE & CO----100,557-100.00%-Dec 31, 2023
CLEAR STREET LLC----73,364-100.00%-Dec 31, 2023
SPARTAN FUND MANAGEMENT INC.----62,987-100.00%-Dec 31, 2023

As of Dec 31 2023, NKGen Biotech's biggest institutional seller is METEORA CAPITAL, LLC. The company sold -2.12M shares of GFOR, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
METEORA CAPITAL, LLC----2,122,715-100.00%-Dec 31, 2023
RIVERNORTH CAPITAL MANAGEMENT, LLC----580,432-100.00%-Dec 31, 2023
DIAMETRIC CAPITAL, LP----471,000-100.00%-Dec 31, 2023
SANDIA INVESTMENT MANAGEMENT LP----471,000-100.00%-Dec 31, 2023
PERISCOPE CAPITAL INC.----347,994-100.00%-Dec 31, 2023
BALYASNY ASSET MANAGEMENT L.P.----310,359-100.00%-Dec 31, 2023
KARPUS MANAGEMENT, INC.----280,525-100.00%-Dec 31, 2023
ALBERTA INVESTMENT MANAGEMENT CORP----200,000-100.00%-Dec 31, 2023
MINT TOWER CAPITAL MANAGEMENT B.V.----200,000-100.00%-Dec 31, 2023
WESTCHESTER CAPITAL MANAGEMENT, LLC----105,266-100.00%-Dec 31, 2023
JPMORGAN CHASE & CO----100,557-100.00%-Dec 31, 2023
CLEAR STREET LLC----73,364-100.00%-Dec 31, 2023
SPARTAN FUND MANAGEMENT INC.----62,987-100.00%-Dec 31, 2023

NKGen Biotech's largest sold out institutional shareholder by shares sold is METEORA CAPITAL, LLC, sold -2.12M shares, valued at -, as of undefined.

NKGen Biotech Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
SPECIAL OPPORTUNITIES FUND, INC.0.23%100,000--Mar 31, 2024
GABELLI DIVIDEND & INCOME TRUST0.08%135,000--Dec 29, 2023
RIVERNORTH OPPORTUNITIES FUND, INC.0.04%48,320--Jan 31, 2024
RiverNorth Specialty Finance Corp0.02%22,29522,295-Sep 30, 2023
Saba Capital Income & Opportunities Fund0.02%55,750--Jan 31, 2024
SCM Trust0.02%65,772--Dec 31, 2023
Investment Managers Series Trust II0.02%200,201--Jan 31, 2024
MERGER FUND0.01%85,305--Mar 28, 2024
MERGER FUND VL0.01%1,034--Mar 28, 2024
Virtus Event Opportunities Trust0.00%9,192--Mar 28, 2024
Listed Funds Trust0.00%10,502--Mar 31, 2024
FIRST TRUST ALTERNATIVE OPPORTUNITIES FUND0.00%2,885--Dec 31, 2023
PRINCIPAL FUNDS, INC.0.00%1,561--Feb 29, 2024

NKGen Biotech's largest mutual fund holder by % of total assets is "SPECIAL OPPORTUNITIES FUND, INC.", owning 100.00K shares, compromising 0.23% of its total assets.

NKGen Biotech Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Sep, 2313-48.00%
30 Jun, 2325-53.70%
31 Mar, 2354-11.48%
31 Dec, 226117.31%
30 Sep, 225210.64%
30 Jun, 224711.90%
31 Mar, 22425.00%
31 Dec, 214011.11%
30 Sep, 2136-

As of 30 Sep 23, 13 institutions are holding NKGen Biotech's shares, representing a decrease of -48.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Sep, 235,326,199-12.66%
30 Jun, 236,098,503-62.35%
31 Mar, 2316,198,5011.70%
31 Dec, 2215,927,6208.97%
30 Sep, 2214,616,38615.68%
30 Jun, 2212,635,4603.44%
31 Mar, 2212,215,58210.17%
31 Dec, 2111,087,44917.84%
30 Sep, 219,409,113-

NKGen Biotech (GFOR) has 5.33M shares outstanding as of 30 Sep 23, down -12.66% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Sep, 2331.65%3.92%
30 Jun, 2328.43%0.50%
31 Mar, 2375.51%1.37%
31 Dec, 2274.25%1.60%
30 Sep, 2268.14%1.96%
30 Jun, 2258.90%1.82%
31 Mar, 2256.94%2.13%
31 Dec, 2151.69%2.69%
30 Sep, 2143.86%-

As of 30 Sep 23, NKGen Biotech is held by 31.65% institutional shareholders, representing a 3.92% growth compared to 30 Jun 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Sep, 234-50.00%
30 Jun, 238-38.46%
31 Mar, 2313-56.67%
31 Dec, 223076.47%
30 Sep, 221741.67%
30 Jun, 2212-
31 Mar, 2212-7.69%
31 Dec, 2113-63.89%
30 Sep, 2136-

4 institutional shareholders have increased their position in GFOR stock as of 30 Sep 23 compared to 8 in the previous quarter (a -50.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Sep, 233-72.73%
30 Jun, 231137.50%
31 Mar, 23833.33%
31 Dec, 226-25.00%
30 Sep, 228700.00%
30 Jun, 221-66.67%
31 Mar, 223-40.00%
31 Dec, 215-
30 Sep, 21--

3 institutional shareholders have reduced their position in GFOR stock as of 30 Sep 23 compared to 11 in the previous quarter (a -72.73% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Sep, 2313-48.00%5,326,199-12.66%31.65%3.92%4-50.00%3-72.73%
30 Jun, 2325-53.70%6,098,503-62.35%28.43%0.50%8-38.46%1137.50%
31 Mar, 2354-11.48%16,198,5011.70%75.51%1.37%13-56.67%833.33%
31 Dec, 226117.31%15,927,6208.97%74.25%1.60%3076.47%6-25.00%
30 Sep, 225210.64%14,616,38615.68%68.14%1.96%1741.67%8700.00%
30 Jun, 224711.90%12,635,4603.44%58.90%1.82%12-1-66.67%
31 Mar, 22425.00%12,215,58210.17%56.94%2.13%12-7.69%3-40.00%
31 Dec, 214011.11%11,087,44917.84%51.69%2.69%13-63.89%5-
30 Sep, 2136-9,409,113-43.86%-36---

NKGen Biotech Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy76$3.29$250.24171,120
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy75$3.32$250.00171,044
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy105$3.33$350.22170,969
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy162$3.07$499.73170,864
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy450$3.19$1.44K693
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy220$3.35$737.00243
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy140$2.85$400.14170,701
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy103$2.91$300.46170,560
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy13$2.92$37.9023
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy10$2.94$29.4010
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy52$2.85$150.00170,457
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy100$2.80$280.00170,405

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy76$3.29$250.24171,120
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy75$3.32$250.00171,044
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy105$3.33$350.22170,969
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy162$3.07$499.73170,864
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy450$3.19$1.44K693
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy220$3.35$737.00243
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy140$2.85$400.14170,701
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy103$2.91$300.46170,560
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy13$2.92$37.9023
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy10$2.94$29.4010
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy52$2.85$150.00170,457
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy100$2.80$280.00170,405

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 15, 2023Park Sangwoodirector, 10 percent owner G-GiftSell2,500,000--10,120,612
Oct 10, 2023Gagnon Pierreofficer Chief Operating OfficerSell11,353$0.32$3.63K-
Oct 10, 2023Gagnon Pierreofficer Chief Operating OfficerSell150,481$6.67$1.00M-
Oct 10, 2023Kim Yong Manofficer CSO and CIOSell---28,384
Oct 10, 2023Kim Yong Manofficer CSO and CIOSell133,450$6.67$890.11K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 15, 2023Park Sangwoodirector, 10 percent owner G-GiftSell2,500,000--10,120,612
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy76$3.29$250.24171,120
Dec 07, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy75$3.32$250.00171,044
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy105$3.33$350.22170,969
Dec 05, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy162$3.07$499.73170,864
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy450$3.19$1.44K693
Dec 05, 2023Graf James Aofficer Interim CFOP-PurchaseBuy220$3.35$737.00243
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy140$2.85$400.14170,701
Nov 28, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy103$2.91$300.46170,560
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy13$2.92$37.9023
Nov 22, 2023Graf James Aofficer Interim CFOP-PurchaseBuy10$2.94$29.4010
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy52$2.85$150.00170,457
Nov 22, 2023Song Paul Y.director, officer Chief Executive OfficerP-PurchaseBuy100$2.80$280.00170,405
Oct 10, 2023Klowden Michaeldirector Buy----
Oct 10, 2023Scott Kathleen D.director Buy----
Oct 10, 2023McNulty Alana B.director Buy----
Oct 10, 2023Gagnon Pierreofficer Chief Operating OfficerSell11,353$0.32$3.63K-
Oct 10, 2023Gagnon Pierreofficer Chief Operating OfficerSell150,481$6.67$1.00M-
Oct 10, 2023Kim Yong Manofficer CSO and CIOSell---28,384
Oct 10, 2023Kim Yong Manofficer CSO and CIOSell133,450$6.67$890.11K-

The last insider sell of NKGen Biotech's stock was made by Park Sangwoo on Dec 15 2023, selling 2,500,000 shares at - per share (valued at -). The last insider buy of GFOR was made by Song Paul Y. on Dec 07 2023, buying 76 shares at $3.29 per share (worth $250.24).

NKGen Biotech Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 20231211200.00%
Q3 20232825.00%
Q2 2022---
Q3 2021-2-
Q2 2021105200.00%

12 total buy trades, and 1 total sell trades (buy/sell ratio of 12.00%) were made by NKGen Biotech's insiders, as of Q4 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 202312--
Q3 2023---
Q2 2022---
Q3 2021---
Q2 202110--

As of Q4 2023, Insider owners conducted 12 open market buy trades and 0 open market sell trades of NKGen Biotech's stocks.

NKGen Biotech Peer Ownership


TickerCompany
ERESAbacus Life, Inc.
LCAAL Catterton Asia Acquisition Corp
DHACDigital Health Acquisition Corp.
FXCOFinancial Strategies Acquisition Corp.
VMCAValuence Merger Corp. I

GFOR Ownership FAQ


NKGen Biotech is owned by institutional shareholders (31.65%), insiders (41.42%), and public (26.92%). The largest institutional shareholder of NKGen Biotech is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is SPECIAL OPPORTUNITIES FUND, INC. (0.23% of total shares).

NKGen Biotech's major institutional shareholders are JPMORGAN CHASE & CO, KARPUS MANAGEMENT, INC., BALYASNY ASSET MANAGEMENT L.P., RIVERNORTH CAPITAL MANAGEMENT, LLC, and ALBERTA INVESTMENT MANAGEMENT CORP. The top five shareholders own together 0% of the company's share outstanding.

As of Sep 2023, there are 13 institutional shareholders of NKGen Biotech.

JPMORGAN CHASE & CO owns 0 shares of NKGen Biotech, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).

As of Dec 2023, KARPUS MANAGEMENT, INC holds 0 shares of NKGen Biotech (GFOR), compromising 0% of the company, valued at $0.

BALYASNY ASSET MANAGEMENT L.P is the third largest holder of NKGen Biotech. The company owns 0 of the company's shares outstanding (worth $0).